BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Biotechnology

Healthcare
$7.30 +1.02%

+$0.09 today

Market cap
$1.88B
Beta
0.56
P/E (TTM)
-4.8
EPS (TTM)
-$1.89
52W Low $6.00High $10.32

Volume 2.95M

Average 4.85M

BCRX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

BioCryst Pharmaceuticals, Inc.NASDAQ: BCRX

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares growth accelerates

Q2 FY2026 weighted avg shares of 254.48M shares rose 21.5% year over year, ahead of the +10.2% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 5.0% from the prior quarter. Over 3 fiscal years it compounded at +4.1% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +21.5% holds above the trailing-twelve-month pace of +10.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
254.48M+5.0% QoQ
Last fiscal yearDec 2025
209.89M+1.5% YoY
LTMJun 2026
229.47M+10.2% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.5%——
1 year+1.5%——
3-year CAGR+4.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
209.89M USD
Year-over-year change
+1.5%
4-year CAGR
+4.0%

Weighted Avg Shares vs competitors

How BCRX compares with its peers on the latest reported figures

  • BCRX's LTM Jun 2026 weighted avg shares of 229.47M shares is the highest of the 4 companies compared; the peer median is 80.03M shares.
  • Its year-over-year change of +10.2% is the 2nd highest of 4, against a peer median of +3.1%.
  • Over three fiscal years its annual growth of +4.1% compares with a peer median of +1.5%.
BCRX Competitors Peer median
Weighted Avg Shares for BCRX and competitors
Company Period LTM YoY 3-year CAGR
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026229.47M +10.2%+4.1%
VIRVir Biotechnology, Inc.LTM Mar 2026140.99M +3.1%+1.5%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 202680.03M -5.4%-0.7%
PHVSPharvaris N.V.LTM Sep 202665.72M +16.6%+20.8%
Peer median (excluding BCRX) 80.03M+3.1%+1.5%

Competitors are the stored peer set for BCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue157.17M270.83M331.41M450.71M874.84M
Cost of Revenue7.26M6.59M4.66M12.49M19.08M
Gross Profit149.91M264.23M326.75M438.23M855.76M
Gross Margin95.4%97.6%98.6%97.2%97.8%
Research & Development208.81M253.3M216.57M174.64M166.13M
Selling, General & Admin118.82M159.37M213.89M266.13M348.65M
Operating Expenses327.63M412.67M430.46M440.77M514.77M
Depreciation & Amortization777K1.44M1.66M1.25M1.39M
EBITDA(121.74M)(143.85M)(116.34M)12.81M347.65M
EBITDA Margin-77.5%-53.1%-35.1%2.8%39.7%
Operating Income(177.72M)(148.44M)(103.71M)(2.54M)340.99M
Operating Margin-113.1%-54.8%-31.3%-0.6%39.0%
Interest Income62K5.13M15.78M14.75M10.67M
Interest Expense59.29M99.09M108.24M98.52M78.87M
Other Income / Expenses(4.09M)(95.95M)(122.52M)(84.41M)(73.6M)
Income Before Tax(181.81M)(244.38M)(226.23M)(86.95M)267.39M
Pre-Tax Margin-115.7%-90.2%-68.3%-19.3%30.6%
Income Tax Expense2.25M2.73M310K1.93M3.53M
Net Income(184.06M)(247.12M)(226.54M)(88.88M)263.86M
Net Margin-117.1%-91.2%-68.4%-19.7%30.2%
EPS (Basic)(1.03)(1.33)(1.18)(0.43)1.26
EPS (Diluted)(1.03)(1.33)(1.18)(0.43)1.21
Weighted Avg Shares179.12M185.91M192.2M206.7M209.89M
Weighted Avg Shares (Diluted)179.12M185.91M192.2M206.7M218.58M

BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Intrinsic Alpha fair value

Locked

Current Price

$7.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.